明德生物拟收购湖南蓝怡51%股权 横向拓展产业链

Group 1 - The company signed a purchase agreement to acquire 51% of Hunan Lanyi Medical Equipment Co., Ltd. through capital increase and equity acquisition, making it a subsidiary included in the consolidated financial statements after the first phase of acquisition [1] - The total transaction price for acquiring 51% of Hunan Lanyi is 35.701 million yuan [1] - Hunan Lanyi focuses on the research, production, and service of IVD instruments and reagents, particularly in glycated hemoglobin testing, utilizing high-performance liquid chromatography (HPLC) technology [1] Group 2 - The core businesses of the company and the target company complement each other, covering the entire process from pre-hospital emergency care to in-hospital diagnosis, post-hospital follow-up, and home management [2] - This transaction will enable the company to achieve horizontal expansion of its industrial chain, enhancing its comprehensive service capabilities for medical institutions [2]